MAI Capital Management’s Matinas BioPharma MTNB Stock Holding History

MAI Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$1	–	3711
2026 Q1	$1	Hold	2	–	–	﹤0.01%	5012
2025 Q4	$2	Hold	2	–	–	﹤0.01%	4349
2025 Q3	$4	Hold	2	–	–	﹤0.01%	3796
2025 Q2	$2	Buy	+2	New	+$1	﹤0.01%	3951

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

MAI Capital Management's MTNB Position: Q2 2026 in Review

MAI Capital Management sold out of Matinas BioPharma (MTNB) in Q2 2026, closing a stake of 2 shares — an estimated $1 sold.

MAI Capital Management first reported a position in MTNB in Q2 2025 and held it in 4 quarters. The position peaked at $4 in Q3 2025. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

MAI Capital Management reported no remaining Matinas BioPharma position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 2 Matinas BioPharma shares in Q2 2026, an estimated $1.
MAI Capital Management first reported a position in Matinas BioPharma in Q2 2025 and held it in 4 quarters.
MAI Capital Management's Matinas BioPharma position peaked at $4 in Q3 2025.
25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.